LEVERKUSEN, Germany (Reuters) – the quarterly profit
Bayer, the pharmaceutical main Germany, failed with
the expectations because of the low sales volumes in
its chemical Division, but the firm is confident in the
launches of new drugs to improve their performance in
the next few years.
Adjusted profit for the fourth quarter before
interest, taxes, depreciation and amortization (EBITDA) for
the Group dropped a 8.8% to 1540 million euros (2,060
million dollars), under the average estimate of 1,620
$ billion in a Reuters poll.
The group, leading manufacturer MaterialScience unit
world of transparent plastics and foam chemicals for
lights of cars and sports eyewear, suffered a fall from a 64 by
% of its profit for the fourth quarter by the rise of the
prices of raw materials.
On Tuesday, the group said that it expected a slight increase
of its EBITDA adjusted this year, with a rise in sales of
around 3 percent, adjusted for variations
foreign exchange and acquisitions.
Bayer has said that its most promising drugs,
headed by the anti-clotting pill Xarelto, have a
maximum combined annual sales potential that skirts the
€5 billion, but that this year is they notice very little.
Market research has shown that Xarelto had a
starting slow in comparison with its rival Pradaxa, Boehringer
Ingelheim, affecting market expectations of a
a 3.2 percent advance in the EBITDA adjusted Group for
this year.
Pills both compete in the mass market for the
prevention of stroke in patients with a common disorder in the
rhythm heart. It is also likely that they face one rival
box with Eliquis, a product developed by Bristol-Myers
Squibb and Pfizer.
Also on Tuesday, Bayer said it expects an increase in
your sales and gain adjusted 2013.
(1 dlr = 0,7466 EUR)
